Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine

Basit Öğe Kaydı
dc.contributor.authorKes, S
dc.contributor.authorCaglar, N
dc.contributor.authorCanberk, A
dc.contributor.authorDeger, N
dc.contributor.authorDemirtas, M
dc.contributor.authorDortlemez, H
dc.contributor.authorKiliccioglu, B
dc.contributor.authorKozan, O
dc.contributor.authorOvunc, K
dc.contributor.authorTurkoglu, C
dc.date.accessioned2019-10-27T19:02:21Z
dc.date.available2019-10-27T19:02:21Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Hypertension is one of the most important causes of cardiovascular disease, and treatment of hypertension leads to a significant reduction in cardiovascular mortality and morbidity. Although calcium channel blockers are regarded as an important part of the therapeutic armamentarium against cardiovascular diseases, and are among the most frequently prescribed anti hypertensive medications, concern has been aroused about these drugs, particularly the short-acting dihydropyridine derivatives. However, the value of nifedipine GITS (Adalat-Crono*), the long-acting dihydropyridine, is in need of being re-established. Objective: To compare the effectiveness, safety and tolerability of once-daily nifedipine and amlodipine treatment in patients with mild-to-moderate essential hypertension. Design: Randomised multicentre trial with an open comparison of treatments for 12 weeks, with a preceding placebo run-in period of 2 weeks (patients on beta-blockers at the time of enrolment entered a mandatory 2-week wash-out period before being allowed in the placebo run-in period; this wash-out period was one week for patients using any antihypertensive medication other than beta-blockers).en_US
dc.identifier.doi10.1185/030079903125001677en_US
dc.identifier.endpage237en_US
dc.identifier.issn0300-7995
dc.identifier.issue3en_US
dc.identifier.pmid12803737en_US
dc.identifier.startpage226en_US
dc.identifier.urihttps://doi.org/10.1185/030079903125001677
dc.identifier.urihttps://hdl.handle.net/11454/38000
dc.identifier.volume19en_US
dc.identifier.wosWOS:000183228900011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLibrapharmen_US
dc.relation.ispartofCurrent Medical Research and Opinionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectamlodipineen_US
dc.subjectantihypertensive agentsen_US
dc.subjectcalcium channel blockersen_US
dc.subjectclinical trialsen_US
dc.subjectGITSen_US
dc.subjecthypertension, essentialen_US
dc.subjectnifedipineen_US
dc.titleTreatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu